Inactive patients were at a higher risk for inactivity-related comorbid conditions, including obesity and diabetes, as well ...

Non-transfusion-dependent thalassemia encompasses three clinically distinct forms -- beta-thalassaemia intermedia, hemoglobin ...

LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage ...

Fintel reports that on January 21, 2025, Cantor Fitzgerald downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) ...

Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of diseases and adverse health ...

Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and EnergyFunding supports a novel ...

EQS-News: EVOTEC SE / Key word (s): Miscellaneous Evotec receives grant from Korean Government to develop novel antibody-based treatments for lung diseases 22.01.2025 / 07:30 CET/CEST The issuer is ...

Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and EnergyFunding supports a novel collaborati ...

Below is a review of novel drug and biological products approved by the Food and Drug Administration (FDA) in 2024. The list includes several groundbreaking therapies that are expected to change the ...

There’s always a bit of wonkiness in the days and weeks after stopping the pill as your body readjusts to life without a ...